Melchiorri Daniela, Rocke Tamarie, Alm Richard A, Cameron Alexandra M, Gigante Valeria
Department of Physiology and Pharmacology, Sapienza University of Rome, Rome, Italy; AMR Division, World Health Organization, Geneva, Switzerland.
AMR Division, World Health Organization, Geneva, Switzerland.
Lancet Microbe. 2025 Mar;6(3):100992. doi: 10.1016/j.lanmic.2024.100992. Epub 2024 Oct 22.
Antimicrobial resistance continues to evolve and remains a leading cause of death worldwide, with children younger than 5 years being among those at the highest risk. Addressing antimicrobial resistance requires a comprehensive response, including infection prevention efforts, surveillance, stewardship, therapy appropriateness and access, and research and development. However, antimicrobial research and development is limited and lags behind the output of other fields, such as that of cancer or HIV research. The 2023 WHO analysis of the global antibacterial clinical pipeline serves as a tool to monitor and guide research and development efforts. The analysis emphasises the remaining gaps in developing a robust and effective antibacterial drug pipeline, drawing insights from trend analyses and assessment of the innovation potential of candidate antimicrobials. In the present analysis, we evaluated the activity of antibiotics against the new WHO bacterial priority pathogens list 2024, which reflects changing trends in resistance patterns, distribution of bacterial infections, and the emergence of new resistance mechanisms.
抗菌药物耐药性持续演变，仍然是全球主要死因之一，5岁以下儿童是风险最高的群体之一。应对抗菌药物耐药性需要全面应对，包括感染预防措施、监测、管理、治疗适宜性和可及性，以及研发。然而，抗菌药物研发有限，落后于癌症或艾滋病毒研究等其他领域的产出。2023年世界卫生组织对全球抗菌药物临床研发管线的分析是监测和指导研发工作的工具。该分析强调了在建立强大而有效的抗菌药物研发管线上仍然存在的差距，从趋势分析和候选抗菌药物创新潜力评估中汲取见解。在本分析中，我们评估了抗生素对2024年世界卫生组织新的细菌重点病原体清单的活性，该清单反映了耐药模式的变化趋势、细菌感染的分布以及新耐药机制的出现。
